CAR-T Therapy Target Proteins

Chimeric antigen receptor T (CAR-T) cell therapy is a major breakthrough in cancer treatment, especially against hematological malignancies, which results in significant, long-term anti-tumor effects with higher target specificity. CD19 and BCMA are the most common targets for CAR-T cell therapy, and many new therapeutic targets are being explored. CAR is a genetically engineered artificial receptor molecule whose function is to guide immune effector cells (such as T lymphocytes) to recognize and eliminate cells expressing specific target antigens, resulting in T lymphocyte activation and a powerful anti-tumor response.